BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6218206)

  • 1. Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells.
    Medof ME; Lam T; Prince GM; Mold C
    J Immunol; 1983 Mar; 130(3):1336-40. PubMed ID: 6218206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Medof ME; Prince GM; Mold C
    Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition for immune complexes by red cells in human blood.
    Medof ME; Oger JJ
    J Clin Lab Immunol; 1982 Jan; 7(1):7-13. PubMed ID: 7069779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
    Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
    Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative pathway-mediated rebinding of immune complexes to human red blood cells.
    Medof ME; Prince GM
    Immunology; 1983 Sep; 50(1):1-9. PubMed ID: 6411608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
    Spycher MO; Nydegger UE
    Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement fixation by small, DNase-resistant DNA-anti-DNA immune complexes.
    Horgan C; Emlen W
    Mol Immunol; 1987 Feb; 24(2):109-16. PubMed ID: 3497335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of recombinant interleukin-1 beta to the third complement component and alpha 2-macroglobulin after activation of serum by immune complexes.
    Borth W; Urbanski A; Prohaska R; Susanj M; Luger TA
    Blood; 1990 Jun; 75(12):2388-95. PubMed ID: 1693530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells.
    Medof ME; Prince GM; Oger JJ
    Clin Exp Immunol; 1982 Jun; 48(3):715-25. PubMed ID: 7116690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
    Fries LF; Prince GM; Gaither TA; Frank MM
    J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
    Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of processing by erythrocyte C3b/C4b receptors (CR1) on binding of immune complexes to Raji cells and polymorphonuclear granulocytes.
    Rasmussen JM; Jepsen HH; Svehag SE
    Scand J Immunol; 1987 Oct; 26(4):437-44. PubMed ID: 2961050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of complement-solubilized immune complexes with CR1 receptors on human erythrocytes. The binding reaction.
    Jepsen HH; Svehag SE; Jarlbaek L; Baatrup G
    Scand J Immunol; 1986 Jan; 23(1):65-73. PubMed ID: 2939551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The covalent interaction of C3 with IgG immune complexes.
    Vivanco F; Muñoz E; Vidarte L; Pastor C
    Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the lymphocyte membrane receptor for factor H (beta 1H-globulin) with an antibody to anti-factor H idiotype.
    Lambris JD; Ross GD
    J Exp Med; 1982 May; 155(5):1400-11. PubMed ID: 6461713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.